ArthroCBD Shares Study’s Findings for Arthritis Awareness Month
Ryan Allway
May 24th, 2021
News
BOULDER, Colo., May 24, 2021 /PRNewswire/ — Arthritis is one of the most widespread health conditions in the United States and affects one in four adults, according to the CDC. That’s over 54 million men and women. There are common misconceptions around Arthritis, including what it’s like to live with it. ArthroCBD recently performed quantitative and qualitative studies to “debunk” these myths. Throughout the month, ArthroCBD will share details of the findings as part of the “Celebrate Life Without Compromises” campaign.
A common myth is that arthritis only impacts the hands and knees. While the majority of people experience this, symptoms can be felt anywhere on the body and weight-bearing joints are the most common. Research shows that symptoms are most present in the form of joint pain and inflammation, which commonly occur in the knees, hands, hips and along the spine.
Another misconception about living with arthritis is that it’s just pain, and you should be able to work through it. One patient surveyed by Opticann says, “it can feel like a constant aching pain and stiffness… it hurts every day.”
15% of those surveyed experience pain in their feet and almost all of them (94%) report that they are frequently in pain. 26% of those surveyed report pain in their torso, head or shoulders. Those who experience pain in these areas experience it more frequently, with half managing their pain on a daily basis.
While there are stigmas to challenge, arthritis and pain sufferers are empowered to find their best treatment option. Research shows that ‘long-term relief’ and ‘limited side effects’ are rated as the most important treatment characteristics. Most arthritis and pain patients have tried between 2-4 different types of treatment for their condition. 32% of people stop after they have tried one treatment, and only 11% of pain and arthritis sufferers surveyed are happy with their current pain treatment.
When it comes to CBD based healthcare products, 97% of consumers with Arthritis are interested in learning more. Only 15% have tried CBD. Four in every five respondents feel confident making their treatment decisions on their own.
The compelling data showed that patients are interested in finding solutions that are well tested and safe without harsh impact to their bodies. ArthroCBD hopes to be a solution for those seeking symptomatic relief and will continue to prioritize research and clinical studies to do so.
About ArthroCBD
ArthroCBD is a subsidiary of Opticann Inc., a Colorado-based oral and topical cannabinoid company. Opticann sells science-backed products made with the patented VESIsorb® drug delivery system for optimized absorption and stability (bioavailability). Opticann is owned by Heritage Cannabis Holdings Corp., a Toronto-based publicly traded corporation (CSE: CANN) (OTCQX: HERTF). Opticann represents the firm’s US medicinal approach to meet consumer needs.
For more information, please visit arthrocbd.com
CONTACT: Alexis Woody
publicrelations@arthrocbd.com
201-241-2668
SOURCE OptiCann
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Xphyto Therapeutics Corp. was created to bridge the gap between traditional cannabis-based medicine and modern scientific approaches to therapeutic validation.
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
